Literature DB >> 24140414

Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications.

Rosalinda Madonna1, Raffaele De Caterina.   

Abstract

Sodium-hydrogen exchangers (NHE) are among the main regulators of cell volume and intracellular concentration of hydrogen and sodium ions. By indirectly affecting sodium/calcium exchange across the plasma membrane, NHE can also influence the intracellular concentration of calcium. Excess activation of NHE or inappropriate sodium extrusion due to failure of ATP-dependent Na(+)/K(+) transport system can be deleterious during cardiac or peripheral organ ischemia. Besides being responsible for the regulation of intracellular pH and sodium-calcium inward currents, NHE isoform 1 (NHE-1), which is predominantly expressed in the cardiovascular system, influences the tone of the vessel wall in response to a variety of stimuli, including hypertonic stress. Because of the extensive involvement of NHE-1 in cardiac myocyte contracture and necrosis, stunning, reperfusion arrhythmias, as well as hypertension and myocardial diseases such as diabetic cardiomyopathy, efforts have been made in developing inhibitors of this transporter. We here review the biology and regulation of NHE, focusing on current knowledge of the role of NHE-1 as a potential target in the development of novel compounds that could play a role in cardiovascular homeostasis, both in physiological and pathological conditions.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardioprotection; Cariporide; Hyperosmolar stress; Sodium–hydrogen exchanger

Mesh:

Substances:

Year:  2013        PMID: 24140414     DOI: 10.1016/j.vph.2013.10.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  6 in total

Review 1.  Organic and inorganic transporters of the testis: A review.

Authors:  David M Klein; Nathan J Cherrington
Journal:  Spermatogenesis       Date:  2015-01-07

Review 2.  Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions.

Authors:  Syona S Shetty; Andrew Krumerman
Journal:  Cardiovasc Diabetol       Date:  2022-06-28       Impact factor: 8.949

Review 3.  Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors.

Authors:  Yuling Jing; Ruixue Yang; Wen Chen; Qiang Ye
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

4.  Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.

Authors:  Rosalinda Madonna; Vanessa Doria; Ilaria Minnucci; Angela Pucci; Donato Sante Pierdomenico; Raffaele De Caterina
Journal:  J Cell Mol Med       Date:  2020-09-17       Impact factor: 5.310

Review 5.  Na+/H+ Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure.

Authors:  Huiting Xia; Aqeela Zahra; Meng Jia; Qun Wang; Yunfu Wang; Susan L Campbell; Jianping Wu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15

6.  Exonic deletion of SLC9A9 in autism with epilepsy.

Authors:  Meeta Cardon; Karen D Evankovich; J Lloyd Holder
Journal:  Neurol Genet       Date:  2016-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.